These DDI study results, in conjunction with plasma endogenous CP-I and PDA biomarker data, suggest that ritlecitinib does not inhibit BCRP, OATP1B1, and OAT3, despite an in vitro assessment surpassing the regulatory DDI risk cutoff of these transporters. This evidence concerns the gene SLC22A8 and Patent ductus arteriosus.